Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Nomir Medical Technologies Granted Second US Patent on Core Noveon Technology

Thursday, January 08, 2009

Waltham, MA -- Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today that the United States Patent and Trademark Office (USPTO) has granted a central patent to Nomir that further protects its core Noveon technology. The Noveon is a light-based system that photo-biologically targets the elimination of bacterial and fungal infections through a unique, near-infrared, photo-inactivation effect, while preserving healthy tissue and promoting recovery.

This patent (#7,470,124) protects the photo-inactivation and eradication of microorganisms as a result of application of Noveon energies through a suite of flexible root canal dispersion tips.

Nomir's Chief Scientific Officer, Dr. Eric Bornstein, said, "The granting of this patent further differentiates Nomir as a photobiology company, as the Noveon's unique action spectrum is proven safe, and is well beyond the mutagenic ultraviolet or photo-thermal ablative wavelengths and power ranges traditionally used for anti-infective indications. We expect this technology will aid the dental community in root canal disinfection procedures, ultimately making root canal procedure outcomes more predictable and successful. To date, Nomir has conducted six different IRB human studies with Nomir's unique and proprietary technologies, which have demonstrated promising results in the areas of onychomycosis, MRSA infection and periodontal disease."

President and CEO Richard Burtt commented, "This new US patent further protects an important portion of Nomir's anti-infective technology assets. The company is in active discussions with strategic corporate partners for the commercialization of this technology in dental markets. Nomir is committed to continuing to build a strong patent portfolio for its Noveon system, including our core focus areas, onychomycosis and MRSA."

In November 2007, Nomir received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to utilize its clinical versions of the Noveon system during contact and non-contact surgical procedures of the skin, subcutaneous tissues and nasal passages in dermatology, plastic surgery, podiatry, and otolaryngology. In December 2008, Nomir received its second 510(k) clearance to utilize the advanced Noveon system for the same indications with enhanced ease and simple operational aspects, eliminating the requirement for a physician to operate the system in most states. The Noveon is designed to effect near-infrared photo-damage and photo-inactivation of bacteria and fungi at energies and temperatures that are safe to normal and healthy tissue. Nomir recently presented detailed data from an IRB MRSA human study at the Termis North America Annual Conference and Exhibition in San Diego and initiated the FDA pivotal study of its Noveon device for the onychomycosis indication in May 2008, an integral step for FDA clearance of the application.

About Nomir

Nomir Medical Technologies, Inc. is a medical device company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nomir's light based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nomir has a broad patent portfolio with pending systems, methods and unique photobiological mechanism claims for near infrared photodamage to bacterial and fungal pathogens.

Forward Looking Statements

Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company's announcements.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free